key: cord-0801185-eyr3u3kq authors: Li, Sicong; Zhao, Ruiwei; Zou, Haidong title: Artificial intelligence for diabetic retinopathy date: 2022-02-05 journal: Chin Med J (Engl) DOI: 10.1097/cm9.0000000000001816 sha: 18b3399c68e713760b1d629c15358a53bea90c2b doc_id: 801185 cord_uid: eyr3u3kq Diabetic retinopathy (DR) is an important cause of blindness globally, and its prevalence is increasing. Early detection and intervention can help change the outcomes of the disease. The rapid development of artificial intelligence (AI) in recent years has led to new possibilities for the screening and diagnosis of DR. An AI-based diagnostic system for the detection of DR has significant advantages, such as high efficiency, high accuracy, and lower demand for human resources. At the same time, there are shortcomings, such as the lack of standards for development and evaluation and the limited scope of application. This article demonstrates the current applications of AI in the field of DR, existing problems, and possible future development directions. Diabetes is a chronic disease with a high prevalence globally. In 2019, there were approximately 463 million adults aged 20 to 79 years with diabetes, [1] and the prevalence is still increasing. [2] By 2040, approximately 600 million people are expected to be diabetic. [3, 4] The prevalence of diabetes in Chinese adults has gradually increased from 9.7% in 2010 [5] to 10 .9% in 2013 [6] and 12.8% in 2018. [7] Diabetes can cause damage to the nerves, blood vessels, and multiple systems in the body. Diabetic retinopathy (DR) is one of the main complications of diabetes. Among diabetic patients globally, it is estimated that 34.6% suffer from DR, among which 10.2% have impaired vision. [8] In China, 18.45% of the population with diabetes have DR, and a longer course of diabetes is associated with a higher prevalence of DR. [9] Respectively, 17.6% [10] and 33.2% [11] of diabetic patients in India and the United States have developed DR. DR is progressive and it is associated with the risk of vision loss and even blindness. It is the main cause of blindness among people of the working age. [4] DR is asymptomatic during the early stages. Therefore, quite a lot of diabetic patients do not undergo regular fundus screening until the DR is severe enough to impair visual acuity. By this time, visual function is often difficult to recover. [12] Therefore, early detection and timely treatment are particularly important to prevent visual impairment caused by DR. The characteristic pathology of DR is retinal vascular abnormalities, including microaneurysms, intraretinal hemorrhages, venous beading, exudates, and neovascularization. [12] Based on severity, DR can be divided into no apparent DR, mild non-proliferative DR (NPDR), moderate NPDR, severe NPDR, and proliferative DR (PDR). Diabetic macular edema (DME) is characterized by the destruction of the blood-retinal barrier and accumulation of fluid in the macular area. [13] It can occur at any stage of DR and threaten vision. Therefore, DME is independently graded [4] and divided into mild, moderate, and severe DME according to the severity. The diagnoses of DR and DME are generally based on the findings of direct and indirect ophthalmoscopy, slit-lamp biomicroscopy with front lenses, fundus photography (FP), optical coherence tomography (OCT), OCT angiography, fluorescein angiography, and B-ultrasound. [14] The ophthalmoscope and slit lamp with front lenses are now widely used because of their low price and accessibility in areas with limited medical resources. FP is currently internationally recognized for DR screening and diagnosis. Owing to its relatively high price, OCT is currently not available for screening in some areas, but it is increasingly valued. The American Academy of Ophthalmology recommends that individuals with type 1 diabetes should undergo annual eye examinations 5 years after the onset of diabetes. Individuals with type 2 diabetes should undergo annual eye examinations at the time of diagnosis. [14] Screening refers to the assessment of the existence or risk of a particular disease in asymptomatic individuals. With early detection and treatment, the outcomes can be improved. [15] Diabetic eye screening in the United Kingdom [16] began in 2003 and covered the entire United Kingdom in 2008. From 2015 to 2016, the program carried out DR screening of 82.8% of the 2,590,082 diabetic patients nationwide. Currently, DR is no longer the main cause of blindness for people aged 16 to 64 years in the United Kingdom. Therefore, extensive screening is believed to help prevent and treat blindness caused by DR. [17] However, compliance with DR screening is generally poor. A U.S. study showed that among the 298,393 patients diagnosed with type 2 diabetes but not DR, nearly half had never undergone an eye examination within the past 5 years; only 15.3% followed the American Academy of Ophthalmology recommendation of having an eye examination once every 2 years. For the patients with type 1 diabetes, one-third did not undergo eye examinations, and only 26.3% of patients followed the American Diabetes Association recommendations for screening. [18] In another previous study, more than onethird of the respondents did not undergo fundus screening regularly. [19] The reasons for the poor compliance of diabetic patients with regular fundus screening recommendations include the lack of understanding of the disease, [20] poor accessibility of medical resources, and insufficient medical insurance coverage. [21] The study by Murchison et al [22] found that patients with more severe DR, impaired vision, and poor blood sugar control had better compliance, which showed that most patients without visual impairment did not realize the importance of regular follow-up. Studies have revealed that 73% of DR patients do not realize that they have DR. [23] In addition, the availability of ophthalmologic screening services affects the compliance of diabetic patients with fundus screening recommendations. [24, 25] One of the ways to enhance the accessibility of fundus screening is telemedicine, which enables patients to undergo fundus examination nearby, and even anytime and anywhere, instead of going to distant hospitals with ophthalmologists. The Singapore Integrated Diabetic Retinopathy Program (SiDRP) obtains fundus images remotely and gets them evaluated by ophthalmologic professionals, which significantly reduces the medical costs. [26] Studies have found that telemedicine is cost effective in a largescale population of >3500 people under 80 years of age. [27] However, traditional telemedicine still relies on human resources to grade the fundus images of patients. In recent years, the development of artificial intelligence (AI) has provided a good alternative for both patients and ophthalmologists to improve the compliance of patients and the efficiency of telemedicine in DR. McCarthy et al [28] first proposed the concept of AI in 1956. Soon afterward, Arthur Samuel proposed the concept of machine learning (ML) in 1959 and pointed out that ML should have the ability to learn statistical techniques without explicit programming. [29] Deep learning (DL) is a branch of ML that is mainly implemented using multi-layer neural networks. A convolutional neural network (CNN) is a DL model suitable for processing images, and it is mainly composed of convolutional layers, pooling layers, and fully connected layers. Commonly used CNN architectures include AlexNet, VGGNet, Inception V1-V4, ResNet, and DenseNet. The CNN model was trained end-to-end on the datasets of labeled images. It achieves higher accuracy by modifying parameters through an error backpropagation algorithm based on the set objective function. Transfer learning is another ML method. In transfer learning, the model is trained in the source domain and transferred to the target domain and fine-tuned, which helps the model to effectively learn and has a good generalization ability from the target domain with a relatively small sample. Compared with traditional ML, an important advantage of DL is that it can automatically learn different levels of effective semantic feature representations of large-scale datasets. AI has been applied to image-based medical fields, such as radiology, [30] dermatology, [31] pathology, [32] and ophthalmology because it is suitable for processing complex images. In the field of ophthalmology, AI can assist in the diagnosis of DR, glaucoma, age-related macular degeneration, and retinopathy of prematurity. Early AI software was developed to identify specific image features. [33] With the development of technology, AI software can learn by itself from datasets with a large number of artificially labeled images. In 2018, the Food and Drug Administration approved the first AI software for DR (IDx-DR). IDx-DR (Digital Diagnostics Inc., Coralville, USA) uses Topcon NW400 to capture fundus images, and the doctor uploads the images to the cloud server. The software provides results according to the images: if the image quality is high enough, and mild or severe DR is detected, the doctor will be prompted to refer the patient to an ophthalmologist; if the severity is not higher than mild DR, it will prompt the patient to retest in 12 months. [34] IDx-DR has shown good sensitivity and specificity in several studies [ Table 1 ]. EyeArt (Eyenuk Inc., Los Angeles, USA) was approved by the Food and Drug Administration in August 2020. [35] Retmarker DR (Retmarker, Coimbra, Portugal) has been certified as a Class IIa medical device in Europe [36] and has been used in the DR screening project in Portugal since 2011. [37] In China, AI-based screening software for DR by Shenzhen SiBionics Co. Ltd. (Shenzhen, China) and the AIbased analysis software for DR by Airdoc (Beijing, China) were also approved in August 2020. [38] Table 1 lists the details of the representative AI systems in the present study, including the training, validation, testing set, as well as sensitivity, specificity, and area under curve (AUC). According to current studies, AI-based diagnosis systems for DR have the advantages of high efficiency, high accuracy, and low demand for human resources. An Australian study found that the AI-based screening system Chinese Medical Journal 2022;135 (3) www.cmj.org for DR only takes about 7 minutes to assess a patient in an endocrinology clinic and shows a higher accuracy as well as higher popularity among patients than manual screening by ophthalmologists. [39] In a study by Abràmoff et al, [40] the sensitivity of the software used in the Iowa Detection Program (IDP) exceeded that of ophthalmologists specializing in retinopathy. Compared with manual work, AI systems are more sensitive and less specific for the diagnosis of DR. [41] Several studies have also shown that AI systems can greatly reduce the workload of manual grading of DR. For example, RetMarker can reduce the workload of manual grading images by 48.42%. [37] Instead of going to specialized hospitals with ophthalmologists, AI systems enable patients to collect fundus photographs or OCT images at a relatively close primary health care clinic, can be used to directly perform grading, and receive further suggestions for follow-up or referral. This characteristic makes it more convenient and efficient for diabetic patients to undergo fundus screening and greatly reduces the workload of ophthalmologists, which can significantly improve the compliance of diabetic patients for fundus screening. During the development of AI-based diagnostic systems for DR, the dataset used should be divided into training, validation, and test sets, and they should not overlap. The training set is used to train the algorithm. The validation set is used for parameter selection and tuning. The testing set is used to evaluate the actual performance of the AI system in clinical settings. [72] Both the training and validation sets are used to develop and optimize the algorithm, while the testing set must be independent of the training and validation sets and cannot be reused; otherwise, it may lead to deviations during the performance evaluation of the algorithm. Owing to the characteristics of DL, the training set should have abundant and high-quality images, which should be evaluated and labeled by ophthalmologists for algorithm development. According to the Chinese guidelines, [ [52] and that sponsored by Google [50, 51] meet the rest of the requirements. The remaining problems associated with the training sets of the existing AI systems include the use of FPs from only a single source [60, 62] and the inclusion of fewer than 500 nonreadable images (or image pairs). [55, 56, 58, 63] Some studies use online datasets as training sets, [59] but with online datasets, it is impossible to have access to the basic information of the patient, such as gender and age. IDP is an early AI system that has been applied to Caucasian and African populations. It mainly grades FP images by identifying characteristic lesions with no DL techniques. Despite its relatively high sensitivity, IDP has a low specificity. [42] IDx-DR adds a CNN based on IDP, which significantly improves the specificity of detection. In prospective clinical studies, the sensitivity of IDx-DR in real clinical settings was lower than that in the testing set, but it still showed satisfactory sensitivity and specificity. [43] EyeArt was the first AI system to detect DR on smartphones. Among 296 patients with type 2 diabetes in India, the sensitivity for referable DR was 99.3% and the specificity was 68.8%, verifying that it is feasible for the system on the smartphone to perform remote DR detection. [47] Referring to the Google algorithm, the threshold can be adjusted to achieve the required sensitivity or specificity. When used for screening, AI and manual work can be combined, as the threshold can be adjusted to a higher sensitivity, and screening can be completed manually. It would be helpful to improve efficiency while ensuring that as few patients with referable DR as possible are missed. Daniel et al used VGGNet to train the algorithm and tested it using an external testing set in ten different countries with an AUC of 0.889 to 0.983, which demonstrated good results for each country. [59] Most current AI-based diagnostic systems for DR are based on FP. FP can only detect DME based on the recognition of hard exudates in the posterior pole, which is limited by the two-dimensional characteristics of FP. Thus, AI systems based on FP may probably miss cases although they cover DME. Compared with FP, OCT has a higher detection rate for DME. [13, 43] Various diagnostic systems currently combine OCT and AI techniques to identify DME [as listed in Table 2] , and, overall, they have good sensitivity, specificity, and AUC. Hwang et al [66] developed an AI system based on OCT that can be used on smartphones, but the system needs to import OCT images into the phone in the first place, which still requires OCT equipment and does not solve the problem of accessibility, which is faced by patients in areas with limited medical resources. Although a large number of AI-based diagnostic systems for DR have been developed, there are still problems to be solved. According to the ICDR standard, retinopathy is further classified into referable (moderate NPDR, severe NPDR, PDR, DME, and ungradable) and non-referable (no apparent DR and mild NPDR) DR, and vision-threatening (severe NPDR and PDR) and non-vision-threatening DR. However, it has not been determined if ICDR is the most suitable classification standard. Li et al [59] believe that since the progression of milder DR is slower than that of severe DR, classification based on ICDR will lead to excessive recommendations for referrals, and early treatment DR study may be a more suitable classification standard. Presently, different studies often use different classification standards, while the different classification standards greatly affect the validity of the algorithm [44] and the evaluation of each algorithm. 3. To date, there is no unified standard for evaluating the validity of AI algorithms. The testing sets of various studies differ significantly. Some studies did not use independent external testing sets, but they used internal validation sets to test the sensitivity, specificity, and AUC of the algorithm. The sensitivity, specificity, AUC, and other indicators reported by different studies were not comparable. Therefore, a standard testing set should be established to evaluate each algorithm. 4. The AI technique has a major unsolvable problem, which is the "black box" phenomenon. This refers to the situation in which the self-learning characteristics of the AI technique make the specific process of assessment by the AI systems unknown, leading to inexplicability. The inexplicability means that people only know the results but cannot judge whether the process of assessment by AI is reasonable or not, let alone intervention. 5. Regarding the misdiagnoses by AI systems, responsibility attribution is another problem that needs to be solved. It seems that neither algorithm developers nor medical staff who use these systems are qualified to assume responsibility alone. Therefore, most AI systems are only used for DR screening. For DR complicated by cataracts and other diseases leading to unclear media or cases where image quality is low due to poor cooperation of the patient, the applicability and reliability of AI-based diagnostic systems are greatly limited, and the only solution is turning to an ophthalmologist. 6. Information security is an issue that cannot be ignored when evaluating AI systems. If AI systems are used to conduct extensive screening of patients with diabetes, a large amount of personal information of patients is likely to be involved. How to ensure that patient information is only used for medical purposes and how to prevent information leakage is a problem that needs to be solved during the development of AI techniques. 7. For most current studies, one AI system can only detect one disease, which means that a patient can only be assessed for a single problem during a fundus examination. If an AI system can detect multiple diseases, the eye examination process will be greatly simplified. Studies have reported detecting other ophthalmic diseases during the screening of DR, which can simultaneously detect age-related macular degeneration and other diseases. [58] Conclusions and prospects AI is of great prospects in screening and diagnosis of DR with several potential future directions. More AI systems will be developed based on portable devices such as smartphones enabling patients to complete DR screening with their own devices at home without the aid of medical workers, which leads to a great reduction in the require- -19) , such telemedicine is of growing importance and would bring considerable benefits and convenience to both patients and medical workers. Currently, most AI-assisted DR screening systems are based on traditional fundus imaging. With the development of novel examination techniques, AI-based systems may cover more varieties of examinations, including multispectral fundus imaging and OCT, and the accuracy could also be improved by the combination of different examinations. In addition to the existing AI-assisted screening systems, this technology will also take an essential role in the diagnosis of DR. In current studies, AI-based systems show better sensitivity than ophthalmologists [40] and have the potential to exceed ophthalmologists in accuracy. Therefore, the AI-assisted diagnosis systems can support ophthalmologists to make diagnoses more accurately and efficiently. In conclusion, for countries with existing DR screening programs, the proper use of AI-based diagnostic systems is expected to greatly reduce the burden of human resources and improve efficiency. In general, the application of AI techniques to DR has great prospects. However, the current datasets used to develop AI algorithms are relatively limited. To apply AI-based diagnostic systems for DR more widely in clinical practice, it is necessary to make full use of clinical resources, establish more heterogeneous datasets, and improve the standards for image quality and labeling. AI systems are more normative and effective. The conditions for replacing ophthalmologists with AI systems are still immature. Therefore, combining the AI techniques with manual work is more realistic and beneficial at the initial stage of applying AI to clinical practice. International Diabetes Federation Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review Diabetic retinopathy Prevalence of diabetes among men and women in China Prevalence and correlates of suicidal ideation among college students: a mental health survey in Jilin Province Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American diabetes association: national cross sectional study Global prevalence and major risk factors of diabetic retinopathy Prevalence, risk factors and burden of diabetic retinopathy in China: a systematic review and meta-analysis Prevalence of diabetic retinopathy in urban India: the Chennai urban rural epidemiology study (CURES) eye study, I Diabetic retinopathy in a multi-ethnic cohort in the United States Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings Diabetic macular oedema San Francisco: American Academy of Ophthalmology Preferred Practice Patterns Committee Screening for diabetic retinopathy Diabetic Eye Screening: Programme Overview The English national screening programme for diabetic retinopathy 2003-2016 Eye care utilization among insured people with diabetes in the Patterns of adherence to diabetes vision care guidelines: baseline findings from the diabetic retinopathy awareness program Barriers for adherence to diabetic retinopathy screening among Saudi adults Characteristics associated with adherence to annual dilated eye examinations among US patients with diagnosed diabetes Non-adherence to eye care in people with diabetes Diabetic retinopathy and age-related macular degeneration in the U.S Disparities in adherence to screening guidelines for diabetic retinopathy in the United States: a comprehensive review and guide for future directions Factors influencing patient adherence with diabetic eye screening in rural communities: a qualitative study Cost-effectiveness of a national telemedicine diabetic retinopathy screening program in Singapore Evaluation of telemedicine for screening of diabetic retinopathy in the Veterans health administration A Proposal for the Dartmouth summer research project on artificial intelligence Some studies in machine learning using the game of checkers Artificial intelligence in radiology Artificial intelligence in dermatology: a primer Artificial intelligence in digital pathology -new tools for diagnosis and precision oncology Automated detection of microaneurysms in digital red-free photographs: a diabetic retinopathy screening tool FDA permits marketing of artificial intelligence-based device to detect certain diabetes-related eye problems. U.S. Food and Drug Administration Food and Drug Administration Screening for diabetic retinopathy in the central region of Portugal. Added value of automated "disease/no disease" grading Announcement of the State Food and Drug Administration on Approval of Registration of 96 Medical Devices Feasibility and patient acceptability of a novel artificial intelligencebased screening model for diabetic retinopathy at endocrinology outpatient services: a pilot study Automated analysis of retinal images for detection of referable diabetic retinopathy Application of deep learning image assessment software VeriSee TM for diabetic retinopathy screening Results of automated retinal image analysis for detection of diabetic retinopathy from the Nakuru study Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices Validation of automated screening for referable diabetic retinopathy with the IDx-DR device in the Hoorn diabetes care system Improved automated detection of diabetic retinopathy on a publicly available dataset through integration of deep learning EyeArt: automated, high-throughput, image analysis for diabetic retinopathy screening Automated diabetic retinopathy detection in smartphone-based fundus photography using artificial intelligence Automated diabetic retinopathy screening and monitoring using retinal fundus image analysis The value of automated diabetic retinopathy screening with the EyeArt system: a study of more than 100,000 consecutive encounters from people with diabetes Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs Performance of a deep-learning algorithm vs manual grading for detecting diabetic retinopathy in India Grader variability and the importance of reference standards for evaluating machine learning models for diabetic retinopathy Improved automated screening of diabetic retinopathy Artificial intelligencebased screening for diabetic retinopathy at community hospital Artificial intelligence of diabetic retinopathy image recognition used in the real world (in Chinese) Artificial intelligence-enabled screening for diabetic retinopathy: a real-world, multicenter and prospective study Diabetic retinopathy screening using artificial intelligence and handheld smartphone-based retinal camera Development and validation of a deep learning system for diabetic retinopathy and related eye diseases using retinal images from multiethnic populations with diabetes An automated grading system for detection of vision-threatening referable diabetic retinopathy on the basis of color fundus photographs Artificial intelligence on diabetic retinopathy diagnosis: an automatic classification method based on grey level cooccurrence matrix and naive Bayesian model Automated identification of diabetic retinopathy using deep learning Clinical evaluation of artificial intelligence system based on fundus photograph in diabetic retinopathy screening Deep learning fundus image analysis for diabetic retinopathy and macular edema grading Predicting optical coherence tomography-derived diabetic macular edema grades from fundus photographs using deep learning Identifying medical diagnoses and treatable diseases by image-based deep learning Smartphone-based diabetic macula edema screening with an offline artificial intelligence Optical coherence tomography-based diabetic macula edema screening with artificial intelligence DMENet: diabetic macular edema diagnosis using hierarchical ensemble of CNNs Detection of morphologic patterns of diabetic macular edema using a deep learning approach based on optical coherence tomography images Clinically applicable deep learning for diagnosis and referral in retinal disease Fully automated detection of retinal disorders by image-based deep learning Intelligent medicine special committee of China medicine education association and national key research and development program of China "development and application of ophthalmic multimodal imaging, artificial intelligence diagnosis and treatment system" project team. Guidelines for artificial intelligent diabetic retinopathy screening system based on fundus photography (in Chinese) Artificial intelligence for diabetic retinopathy None.